ScreenerHero

ALDX Aldeyra Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · aldeyra.com
0.9586USD+4.66%Mkt Cap: 57.83M $P/E: —

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, wh…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap57.83M USD
Enterprise Value10.31M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-33.85M USD
Revenue/Share—
Last Price0.9586 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees6
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.33
PEG—
EV/EBITDA-0.43
EV/Revenue—
P/S—
P/B1.46
EPS (TTM)-0.38
EPS (Forward)-0.28
52W Range
0.86192% of range5.930
52W High5.930 USD
52W Low0.8619 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-76.49%
ROA-46.97%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-33.35M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-27.01%
Net Debt-44.95M USD
Net Debt/EBITDA1.89
Balance Sheet
Debt/Equity0.35
Current Ratio4.91
Quick Ratio4.67
Book Value/Sh0.63 USD
Cash/Share0.75 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)6.600 USD
Upside (mean)+588.5%
Target Range2.000 USD – 13.00 USD
2.000+588.5% to mean13.00
# Analysts5
Ownership
Shares Out.60.33M
Float48.95M
Insiders3.60%
Institutions61.54%
Short Interest
Short Ratio5.2d
Short % Float6.17%
Short % Out.5.97%
Shares Short3.60M
Short (prev mo.)3.32M
Technical
SMA 501.449 (-33.8%)
SMA 2002.657 (-63.9%)
Beta1.20
S&P 52W Chg16.45%
Avg Vol (30d)1.42M
Avg Vol (10d)2.12M
Technical Indicators
RSI (14)31.7
MACD-0.1361
MACD Signal-0.1037
MACD Hist.-0.0325
BB Upper1.638 USD
BB Middle1.276 USD
BB Lower0.9134 USD
BB Width56.83%
ATR (14)0.1166 USD
Vol Ratio (20d)0.72x